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 Abstract 
Background: Pneumonia is the leading cause of death in children worldwide and the most 
important pathogen causing the disease is the bacterium Streptococcus Pneumoniae (the 
pneumococcus). This study aimed to determine the carriage rate and the resistance pattern of 
pneumococci in healthy children below 2 years of age in Moshi in northern Tanzania. In this 
region the pneumococcal conjugate vaccine was introduced into the child vaccination 
programme in January 2013. A second aim was to determine if there were any correlations 
between carriage of the bacteria and health status or socio-economic factors.  
Methods: During October and November 2013, 150 randomly selected healthy children were 
included in the study. The children were recruited from three different health clinics in Moshi. 
A nasopharyngeal sample was taken from the children and a questionnaire was given to the 
parents. The samples were then cultured for pneumococci and the resistance pattern of the 
bacteria was determined at the clinical laboratory at Kilimanjaro Christian Medical Centre 
(KCMC) in Moshi. 
Results: The carriage rate of pneumococci in the nasopharynx among the children was 29%. 
The rate of pneumococcal strains with reduced susceptibility against penicillin was 37 %, the 
rates against ceftriaxon and ampicillin were 2% for each.  The rate of pneumococci with 
reduced susceptibility against co-trimoxazole, tetracycline and erythromycin were 95%, 33% 
and 10% respectively. All isolates were sensitive to norfloxacin and clindamycin. The only 
factors significantly more common in children carrying pneumococci than in children without 
pneumococci were malaria and among children aged 0-6 months exclusively breastfeeding. 
Discussion: The rather high rates of non-susceptible bacteria, as shown in this study, confirm 
that penicillin or co-trimoxazole should not be used as empirical treatment of pneumonia in 
this area, while amoxicillin could still be the first drug of choice.  
Conclusion: More restrictions on the antibiotic use may be needed in the Moshi area.  
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 Background 
Streptococcus pneumoniae, also known as the pneumococcus, is a bacterium that can cause a 
wide range of infections, from local manifestations such as otitis media and sinusitis to 
invasive disease such as sepsis or meningitis.(1)  
It is also the most common cause of pneumonia, which is a major global health problem and 
the leading cause of death in children under five years of age.(2) In the year of 2000 the 
estimated number of serious pneumococcal diseases to occur globally was 14.5 million, 
leading to about 826 000 deaths in children aged one month to five years.(3) 
 
The pneumococcus is a gram-positive encapsulated diplococcus. The capsular 
polysaccharides on the surface of the bacteria are the primary factor of virulence and are also 
the basis from which serotyping is made, resulting in 40 serogroups and 93 serotypes.(1) All 
of them have varied ability to cause disease and the distribution of serotypes varies by regions 
and age.(1)   
The pneumococcus frequently colonizes the upper respiratory tract, especially in children, and 
the human nasopharynx is the only natural reservoir for it. S. pneumoniae is transmitted 
between individuals through respiratory droplets, and nasopharyngeal colonization is a first 
step of pathogenesis.(1) Children are often asymptomatic carriers and invasive disease does 
usually not occur without foregoing colonization with the homologous strain.(1) 
Studies show that nasopharyngeal carriage rates of S. pneumoniae varies widely between 
different countries and populations. In for example Kenyan, Turkish and Venezuelan the 
carriage rates in healthy children below five years of age were 23, 28 and 57 % 
respectively.(4-6) In a study from Kampala, Uganda there was a carriage rate of 62 % in the 
healthy study population (7), and in another study done in Dar es Salaam 2010 the carriage 
was 35 % when a population of 300 healthy children under five years of age were sampled.(8) 
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 Pneumococci resistant to antibiotics are an increasing problem all over the world. Pneumonia 
caused by penicillin-resistant S.pneumoniae has been reported to be more lethal in 
hospitalized adult patients than infection due to penicillin-susceptible strains.(9)  
Due to over-prescription and misuse of antibiotics this problem is even greater in low-income 
countries and the reduced efficacy of antibiotics may be a greater challenge for resource-
limited countries since the drugs with the highest levels of resistance often is the cheapest 
antibiotics.(8) 
Adequate antibiotic therapy at the early stage of disease is very important for successful 
outcome, and penicillin or amoxicillin are the first choice of drugs. Amoxicillin is now the 
first line choice because of the high rates of resistance of the cheap and previously much used 
trimethoprim-sulphamethoxazole (Co-trimoxazole).(10)  
Investigations of antibiotic susceptibility of S. pneumoniae in hospitalized children with 
pneumonia is often very difficult, due to sampling limitations and because the children many 
times already have been given antibiotics. Instead, studies investigating the rate of 
nasopharyngeal carriage and penicillin susceptibility of pneumococci in the healthy child 
population provide data of the spread of resistant strains in the whole community.(8) 
 
In the study from Dar es Salaam more than two-thirds of the isolates were penicillin-non-
susceptible pneumococci (PNSP) and multidrug-resistance (resistance to three or more of the 
antibiotics tested) was found in 17 % of the isolates.(8) 
A study done on healthy children in Brussels during 2006-2008 showed that children with 
lower socio-economic status were more likely to carry antibiotic-resistant S. pneumoniae.(11)  
In Rombo district in northern Tanzania the carriage and resistance of S. pneumoniae was 
studied in healthy children below seven years after Azithromycin administration for trachoma 
control in 2000. The carriage rate found was only 11 %.(12) This was a unexpectedly low 
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 carriage rate and a comparative study using the same methods in children of similar age was 
done on a local sugar plantation where the carriage rate instead was 50 %.(12) In the study 
from Rombo district the rates of S. pneumoniae with reduced susceptibility to penicillin and 
co-trimoxazole was 21 % and 42, % respectively.(12)   
Similar resistance rates were shown in a study from Malawi where 21%, of the isolates from 
children under five years visiting health clinics were nonsusceptible to penicillin, 46% were 
nonsusceptible to co-trimoxazole and 22% to tetracycline.(13) 
In the study from Uganda previously mentioned 84 % was PNSP, and resistance to co-
trimoxazole and tetracycline was 84 % and 29 % respectively.(7) 
 
Streptococcus pneumoniae stands for a major part of the pneumonia cases worldwide and was 
in the year of 2010 responsible for 33 % of the childhood pneumonial deaths in low- and 
middle-income countries.(14) A high proportion of deaths due to pneumonia occur early in 
life, 81 % of the incidents are in children under 2 years of age.(10) 
Pneumonia is an acute respiratory tract infection affecting the lungs. When a healthy person 
breathe the small alveoli in the lungs are filled up with air but when suffering from 
pneumonia the alveoli are instead filled up with pus in the affected area leading to difficulty 
to breath and limits oxygen uptake.(2)  
 
Malnutrition, time of breastfeeding, pre-existing illnesses such as HIV and measles, indoor 
pollution and living in crowded homes are all factors that can increase a child’s susceptibility 
to pneumonia.(2) All of this are more common in the sub-Saharan countries and these 
countries have the highest burden of deaths from pneumonia in the world.(10) Fifteen 
countries in the world, all in Asia and sub-Saharan Africa, are responsible for 65 % of the 
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 total episodes of pneumonia and 64 % of the severe cases, and Tanzania is one of these 
countries.(10) 
In year 2010 pneumonia was responsible for 15 % of the deaths among children under five 
years of age in Tanzania.(15) 
 
To lower the number of invasive pneumococcal disease in children vaccines are now 
introduced in many countries.   
There are two different kinds of vaccines against Streptococcus pneumoniae, the 
polysaccharide vaccine and the conjugate vaccines. The polysaccharide vaccine includes the 
23 serotypes most commonly known to cause disease but does not give a long-lasting 
protection and is therefore not recommended for small children.(16) The conjugate vaccine is 
available in three forms, PCV7, PCV10 and PCV13 covering seven, ten and thirteen serotypes 
respectively. PCV13 is the newest of them all and it covers for serotype 
1,3,4,5,6A,6B,7F,9V,14,18C,19A, 19F and 23F.  
Since it is a conjugate vaccine it will activate T-cells and give a long lasting protection also in 
children under two years of age.(16) 
Studies done after the introduction of the vaccines have showed a reduced rate of invasive 
pneumococcal diseases caused by the serotypes included in the vaccines.(17, 18) However a 
rise in carriage of the serotypes not included in the vaccine has also been seen,(19) and a shift 
towards other disease-causing serotypes has been observed.(17, 19) In one study done in the 
United States after introduction of the PCV7 the percentage of invasive pneumococcal disease 
2006-2007 caused by serotypes covered by the PCV7 was 2 % and the number of invasive 
pneumococcal disease caused by  the additional serotypes included in the PCV13 was 63 % in 
children under five years of age.(17, 18) 
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 Studies done after the introduction of PCV13-vaccine have also shown direct and indirect 
effect of the vaccine. A shift towards colonization with other serotypes has been observed, 
although these are not commonly causing disease. (19) The indirect effect, or herd immunity, 
means that even non-vaccinated individuals also get protection of the vaccine through 
diminished spread of the disease-causing serotypes. 
Introduction of the vaccines also affect the spread of resistant bacteria. After the introduction 
of PCV7 and PCV9 reduced levels of penicillin non-susceptible pneumococci were found 
both in vaccinated and unvaccinated individuals, and a reduction in antibiotic use was also 
seen.(20) The serotypes causing disease in children are also the most common ones to be 
antibiotic resistant and there was an increase in intermediate resistant serotypes not included 
in the PCV7 or PCV9 but in the PCV13.(20)  
These studies mainly come from western countries and the indirect effect of the vaccine in 
developing countries where carriage of pneumococci is highly prevalent and the distribution 
of serotypes may be different needs to be further investigated.(21) 
In January 2013, Tanzania introduced the PCV13 into their child vaccination program. 
According to the demographic health survey the total vaccine coverage in the whole country 
was 75 % in 2010. In the northern region the coverage was 80 %.(22)   
 
In Tanzania the under-5 mortality rate declined with 41 % from 137 deaths per 1000 live 
births in 1992-1996 to 81 deaths in 2006-2010. It differs a lot between regions though, the 
Northern region has an under-5 mortality rate at 58 deaths per 1000 live births compared to 
the Southern Highlands or the Lake region with a rate at 102 and 109 respectively.(22) There 
are also several socio-economic factors that make a variance in mortality rates. For example if 
the mother has no education versus secondary school or higher the rates are 97 and 73 deaths 
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 respectively, and if you compare the lowest and highest wealth quintile the rates are 103 and 
84 deaths per 1000 live births, respectively.(22)  
Although a considerable decrease in childhood mortality have been seen, both in terms of all-
cause mortality and specific for pneumonia, more effort still needs to be done to reach the 
forth millennium goal (reduce the child mortality with two thirds between 1990 and 
2015).(10) Despite the number of deaths is declining a larger proportion of deaths is seen in 
sub-Saharan Africa.(23)  
 There are many challenges and obstacles for low-income countries to combat on the way to 
achieve these goals, for example under-developed and weak health care systems cannot easily 
scale up antibiotic coverage for those children who need it most because of the relatively low 
rates of access to health care.(24)  
The PCV13 is now included in the vaccination-program in many countries in order to 
decrease the number of cases of pneumonia and deaths from it. When evaluating the outcome 
it is important to investigate the carriage rates of pneumococci, the serotypes circulating in the 
population before and after the introduction, and if there is any differences in the rates of 
resistant bacteria. This is especially important in countries where the disease-burden is high 
and there is little research on the field.  
 
Aim 
• To investigate the colonization rate and antibiotic susceptibility of S. pneumoniae in 
the nasopharynx of healthy Tanzanian children.  
• Relate the carriage rate to social factors and health status of the children.  
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 Methods 
This was conducted as a cross-sectional study during October and November 2013 in Moshi 
urban district, a town with approximately 200 000 inhibitants by the foot of Kilimanjaro in 
northern Tanzania. Children below 2 years of age coming for routine care such as 
immunization and growth monitoring, seeking healthcare or accompanying a relative were 
included in the study. The children were recruited at one Health centre, Pasua, and two 
dispensaries, Bondeni and Njoro, nearby Moshi. The health facilities were chosen and 
approved by Dr. Benjamin Sana at Moshi Municipal Council. 
 The parents were asked questions from a questionnaire containing questions about health 
status, previous illnesses, neonatal problems, breast feeding, socio-economic status, living 
conditions, vaccinations, antibiotic treatment etc. The weight and length of the children were 
also noted. The questionnaire was constructed together with our supervisors and was before 
the sampling began tested on two children with parents at Kilimanjaro Christian Medical 
Centre (KCMC). The questioning was done in Kiswahili by the two experienced Community 
Health nurses Celina Mayo and Bertha Kiwale, who also took a nasopharyngeal sample from 
each child.  
Of all 351 questioned, 13 parents/guardians refused to participate; leaving a total of 338 
healthy children or children with upper respiratory tract infections that was sampled and 
interviewed. All 338 children were interviewed and sampled regardless of symptoms and the 
separation between healthy children and children with symptoms (described in another 
student report) was done afterwards. 
The samples taken by blue-capped E-swabs (Copan diagnostics, Murrieta, USA), were 
transported cooled from the health facilities to the microbiological laboratory at Kilimanjaro 
Christian Medical Centre in Moshi. The samples were immediately inoculated onto blood 
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 agar plates with 5 % sheep blood where after the E-swabs were frozen in a -20°C freezer. The 
plates were incubated in 5 % CO2 in 34-36 ̊ C for two days, and checked after each day. 5 % 
CO2 atmosphere was obtained by closed jars supplied with CO2 paper sachets (GasPak EZ 
CO2 Container System, Becton Dickinson and Company (BD), Sparks, MD) and CO2 
indicators (BD). Suspected pneumococcal isolates (α-haemolytic, greyish colonies with 
depressed centres) were subcultured on blood agar plates and then re-incubated in 34-36 ̊ C 
with 5 % CO2 overnight. A colony from this pure subculture was cultured on Muller-Hinton 
agar plates (supplied with 5 % defibrinated sheep blood and 20 mg/L β-NAD (Applichem, 
GmbH, Darmstadt, Germany). One Optochin-disc and one Oxacillin-disc (both from Oxiod, 
Hampshire, UK) were put onto the plates. An inhibitory zone around the Optochin-disc of ≥ 
14 mm served as identification of S. pneumoniae. Colonies of S. pneumoniae were then frozen 
at -20 ̊ C in cryotubes containing 1,0 ml of STGG.(25) The STGG freezing medium consisting 
of skim milk powder (BD Difco, USA), tryptone soya broth (Oxoid), glucose, glycerol and 
distilled water.   
A few numbers of identified colonies were suspended in 2 ml sterile Phosphate buffered 
saline to McFarland 0.5. Using a sterile cotton swab, a fraction of the suspension was 
inoculated on Muller-Hinton agar plates for testing of antibiotic susceptibility against 
Trimethoprim-sulphamethoxazole (1,25-23,75 µg), Erytromycin (15 µg), Clindamycin (2 µg), 
Norfloxacin (10 µg) and Tetracycline (30 µg) (all from Oxiod). 
The Oxacillin disc was used for screening of penicillin non-susceptibility and isolates with a 
zone-diameter of < 20 mm were further tested with E-tests for minimal inhibitory 
concentration (MIC) determination for benzylpenicillin, ampicillin and ceftriaxone (all 0.016-
256 μg/mL from Biomerieux, Marcy l'Etoile, France).  
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 Pneumococcus with MIC > 0.06 mg/l was classified as having reduced susceptibility to 
penicillin and if MIC was > 2 mg/l the isolates were classified as resistant.(26) The 
breakpoints used for the disc-diffusion tests and MIC-determination were from the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) from 2013. (26) (Table I and 
II). 
Table 1: Breakpoints according to EUCAST on disc diffusion tests 
Antibiotic 
 
Sensitive 
 (mm) 
Intermediate 
(mm) 
 Resistant 
 (mm) 
Clindamycin  ≥ 19  < 19 
Erytromycin  ≥ 22 19 – 21 < 18 
Norfloxacin ≥ 12  < 12 
Oxacillin ≥ 20   
Tetracycline  ≥ 25 22 – 24 < 21 
Trimethoprim-sulphamethoxazole ≥ 18 15 – 17 < 14 
 
Table II: Breakpoints according to EUCAST on MIC tests 
Antibiotic 
 
Sensitive  
(mg/L) 
Intermediate 
(mg/L) 
Resistant 
(mg/L) 
Ampicillin  ≤ 0.5 0.5 – 2 > 2 
Benzylpenicillin ≤ 0.06 0.06 – 2 > 2 
Cefotaxim ≤ 0.5 0.5 – 2 > 2 
 
Statistical methods 
The data-analysis was done using cross-tabulations in SPSS version 21. Fisher exact test was 
used for comparisons between groups, p-values ≤ 0.05 were counted as significant. 
Ethics 
The parents were informed that participation of the child in the study was voluntary. They 
were also informed that whether or not they chose to participate, the treatment at the clinic 
would not be affected. The children in the study are not able to identify. The parents had to 
sign a consent form before the start of the questioning and sampling. 
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 Ethical approval was obtained from Kilimanjaro Christian Medical College and University 
Ethical Committee; this is presented in the appendix.  
Results 
Recruited children 
150/338 children had no symptoms of respiratory tract infection and were therefore included 
in this study. Half of the children (79/150) were recruited at a dispensary (Bondeni, n=26 and 
Njoro, n=53) and the other half from a health centre (Pasua Health centre, n=71). 
The cause for visiting was growth monitoring for 66 children, vaccination for 65 children, 
OPD (sick children seeking care at “out patient department”) for 8 children and other reasons 
mostly accompanying a family member) for 11 children. All children lived in areas classified as 
urban or semi-urban, none was rural. Other characteristics of the study population are shown 
in table III.  
49 % of the children had been treated with antibiotics within the last three months before the 
study (Table IV). In terms of current or previous diseases no child had had measles and only 
three children had unknown HIV-status, whereas 37% (56/150) of the children had had 
diarrhoea and 21% (32/150) malaria. Almost all children were breastfed (Table IV). Of the 
children aged 0-6 months (n=68) the breastfeeding was exclusive in 37 %, predominantly in 
40 %, whereas 24 % of the children were mix fed.  
Table III. Study Population 
 Healthy children 
n=150 (range) 
 
Age (months) median 
 
 
7 (0-24) 
Weight (kg) median 
 
8.0 (2.0-16.0) 
Length (cm) median 
 
65 (42-87) 
Gender (boys: girls) 82:68 
12 
 
 Nasopharyngeal carriage of pneumococci:  
In the nasopharyngeal samples collected from the healthy children pneumococci was isolated 
in 29% (43/150). 
The relation between pneumococcal carriage and social factors or health status is shown in 
table IV. Malaria was significantly more common in children carrying pneumococci than in 
children without pneumococci (44% versus 12%, p<0.0001). No other disease, including 
previous respiratory tract infection, was associated with pneumococcal carriage. Among the 
68 children aged 0-6 months mixfeeding was significantly more common in the children 
without pneumococci compared to children with pneumococci (p=0.015), whereas exclusively 
breastfeeding tended to be more common in children with nasopharyngeal carriage of 
pneumococci compared to children without pneumococci (p=0.081). No statistical 
significance was seen for any other of the factors investigated in relation to pneumococcal 
carriage.     
 
Table IV Correlation between pneumococcal carriage and social factors 
   
 Pneumococcal carriage p-value 
 Yes 
n = 43 (%) 
No 
 n = 107 (%) 
 
 
Preterma 
 
0 (0) 
 
6 (5.6) 
 
0.18 
Breastfed 41 (95) 99 (93) n.s 
Antibiotic use 
<1 week 
≥1 week-4 weeks 
>4 weeks-12 weeks 
  
2 (4.7)  
11 (26)  
9 (21) 
  
7 (6.5) 
26 (25) 
19 (18) 
 
n.s 
n.s 
n.s 
Recent respiratory tract infectionb 5 (12) 22 (21) n.s 
Hospitalizedc 
Diarrhoea 
Malaria 
2 (4.7) 
39 (36) 
19 (44) 
 
7 (6.5) 
17 (40) 
13 (12) 
 
n.s 
n.s 
< 0.0001 
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 Siblings 25 (58) 63 ( 59) n.s 
Siblings < 5 years 10 (23) 24 (23) n.s 
Four or more persons per room 7 (16) 13 (12)  
Anyone smoking 7 (16) 15 (14) n.s 
Firewoodd 3 (7.0) 8 (7.5) n.s 
Vaccinated against pneumococci 
No 
Yes partial 
Yes fully 
Education mother 
No school 
Primary school 
Secondary school 
University 
 
19 (44)  
8 (19)  
16 (37) 
 
0 (0) 
34 (79) 
9 (21)  
0 (0) 
 
43 (40) 
19 (18) 
45 (42) 
 
3 (2.8) 
67 (63) 
36 (34) 
1 (1.0) 
 
n.s 
n.s 
n.s 
 
n.s 
0.057 
n.s 
n.s 
Education father 
Primary school 
Secondary school 
University 
 
 
 
Breastfeeding 0-6 months 
Exclusive 
Predominatly 
Mixfed 
 
 
25 (58)  
17 (40) 
1 (2.3) 
 
 
n = 16 (%) 
 
9 (56) 
7 (44) 
0 (0) 
 
 
60 (56) 
35 (33) 
12 (11) 
 
 
 n = 52 (%) 
 
 16 (31) 
 20 (39) 
 16 (31) 
 
n.s 
n.s 
0.11 
 
 
p-value 
 
 0.081 
 n.s 
 0.015 
a 
Meaning children born 14 days or more before estimated date. 
b 
Defined as cough with fever, rapid or difficulty breathing or pneumonia during  the past three months 
c 
Admittance to hospital the past three months 
d 
Using firewood for cooking indoors without chimney 
n.s = non significant
 
 
Antibiotic susceptibility:  
The first package of antibiotic-discs and E-tests was delayed in Dar es Salaam for 
approximately three weeks and was therefore not stored cooled properly according to the 
manufactory’s instructions. For that reason new, small packages of discs and E-tests were 
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 transported by passenger plane to Moshi. To investigate if there was any difference in the 
function of the antibiotic discs and strips due to the delay, the old and new discs and E-tests, 
respectively, were both tested on the first ten pneumococcal isolates. No significant difference 
was found between the old and new material and no difference at all regarding classification 
of the pneumococcal strains into Sensitive, Intermediate and Resistant according to the 
breakpoints presented in Table I and II. The results from the dubbeltesting are presented in 
Table V and VI. 
 
Table V: Disc-diffusion dubbeltesting 
Namn Optochin Oxacillin Oxa-
SIR 
SXT SXT-
SIR 
E E-
SIR 
DA DA-
SIR 
NOR NOR-
SIR 
TE TE-
SIR 
1 25 29 S 23 S 29 S 24 S 20 S 32 S 
1 new 25 28 S 23 S 29 S 25 S 20 S 32 S 
2 15 15 R 8 R 12 R 23 S 19 S 19 R 
2 new 15 16 R 6 R 15 R 22 S 19 S 20 R 
5 22 9 R 12 R 26 S 22 S 21 S 14 R 
5 new 21 9 R 13 R 27 S 23 S 21 S 13 R 
7 17 28 S 21 S 28 S 29 S 18 S 33 S 
7 new 17 28 S 24 S 27 S 28 S 18 S 36 S 
9 15 25 S 9 R 30 S 26 S 21 S 36 S 
9 new 15 25 S 8 R 29 S 29 S 22 S 36 S 
10 20 27 S 6 R 35 S 29 S 25 S 39 S 
10 new 20 28 S 6 R 34 S 29 S 25 S 38 S 
14 18 26 S 19 S 29 S 26 S 20 S 34 S 
14 new 18 25 S 20 S 28 S 33 S 20 S 34 S 
16 25 13 R 6 R 31 S 29 S 19 S 33 S 
16 new 26 13 R 6 R 31 S 29 S 25 S 34 S 
28 18 24 S 6 R 23 S 22 S 17 S 38 S 
28 new 18 23 S 6 R 23 S 23 S 18 S 38 S 
30 15 21 S 6 R 30 S 25 S 18 S 33 S 
30 new 15 21 S 6 R 32 S 26 S 18 S 33 S 
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 Table VI: MIC dubbeltesting 
   MIC P    MIC AM    MIC CT 
35 0.125  0.19  0.25 
35 new 0.125  0.19  0.25 
39 0.19  0.125  0.094 
39 new 0.19  0.125  0.094 
47 0.25  0.19  0.125 
47 new 0.25  0.19  0.125 
58 0.19  0.125  0.064 
58 new 0.19  0.125  0.064 
61 0.25  0.125  0.094 
61 new 0.25  0.125  0.094 
63 0.25  0.25  0.008 
63 new 0.25  0.25  0.008 
87 0.94  0.16  1.5 
87 new 0.94  0.16  1.5 
93 0.032  0.016  0.125 
93 new 0.032  0.016  0.125 
101 0.032  8  32 
101 new 0.034  8  32 
106                  0.023                  0.125               8 
106 new      0.023         0.125               8 
 
Antibiotic susceptibility of the pneumococcal strains: 
Of the 43 Streptococcus pneumoniae strains 16 had a zone-diameter for Oxacillin < 20 mm 
and were further tested with Minimal Inhibitory Concentration (MIC) for benzylpenicillin, 
ampicillin and ceftriaxone. All 16 samples (37 %) had MIC > 0.06 mg/L for penicillin and 
were thus classified as PNSP (penicillin non susceptible pneumococci), no one was resistant 
(MIC > 2 mg/L). Only one isolate had reduced susceptibility against ampicillin and one 
isolate against ceftriaxone, MIC 0.94 and 1.5 mg/L respectively. 
Cotrimoxazole, erythromycin, clindamycin, norfloxacin and tetracycline were tested 
according to the disc diffusion test. The rate of pneumococci with reduced susceptibility to 
trimethoprim-sulfametoxazole (Cotrimoxazole) was 95 %. The rates for tetracycline and 
erythromycin were 32 % (where 12 isolates were resistant and two isolates had intermediate 
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 susceptibility) and 10 % (where two isolates were resistant and two isolates had intermediate 
susceptibility) respectively. No isolates with resistance against norfloxacin and clindamycin 
were found. 
Multidrug-resistance, meaning reduced susceptibility to three or more antibiotics, occurred in 
12/43 isolates giving a rate of 28 %. The susceptibility testing results are presented in figure I. 
 
Figure I: Rates of pneumococcal isolates with reduced susceptibility (intermediate or 
resistant) against antibiotics
 
DA= Clindamycin 
E= Erythromycin  
NOR= Norfloxacin  
SXT= Cotrimoxazole/ trimethoprim-sulphametoxazole  
TE= Tetracycline 
AM = Ampicillin 
P = Benzylpenicillin 
TX = Ceftriaxone  
 
  
0% 
10% 
0% 
95% 
33% 
2% 
37% 
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30%
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 Discussion 
Carriage of Streptococcus pneumoniae has been studied all over the world, but few studies 
have been conducted in low-income countries, especially after the introduction of the 
pneumococcal conjugate vaccine. This study investigated the carriage rate in 150 healthy 
children below two years of age at three different health facilities in Moshi, northern Tanzania 
after the introduction of the conjugate vaccine. Isolated pneumococci were further tested for 
antibiotic susceptibility in order to investigate the spread of resistant bacteria in the society, 
and the carriage was also related to social factors and health status. No significant difference 
in carriage rate was noticed between the three health clinics which suggest that the carriage 
rate and resistance pattern found in this study reflects the true carriage and resistance rate in 
the Moshi region. 
 
The children included in this study had a nasopharyngeal carriage rate at 29 %. This is lower 
compared to the studies on healthy children from Kenya and Uganda which showed a carriage 
rate at 57 % and 62 % respectively,(4, 7) but in line with the studies on healthy children from 
Turkey, Venezuela and Dar es Salaam which showed a carriage rate at 23 %, 28 % and 35 % 
respectively.(5, 6, 8) The relatively low carriage rate in the present study could be explained 
by the fact that the included children were quite young (median 7 months). The carriage rates 
of pneumococci increases during the first year of life and is the highest in children at 2-3 
years of age.(27) 
 
Among the 43 pneumococcal isolates there were rather high rates of reduced susceptibility to 
antibiotics. More than one-third of the isolates had reduced susceptibility against penicillin. 
This is lower than the 68 % in Dar es Salaam but higher than the 21 % found in Rombo 
district in northern Tanzania.(8, 12)  The rate of pneumococci with reduced susceptibility 
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 against cotrimoxazole, tetracycline and erythromycin were 95%, 33% and 10% respectively in 
this study, which is even higher than the numbers from Dar es Salaam where the numbers 
were 83 %, 10 % and 6 % respectively.(8) Also the multidrug resistance is even somewhat 
higher in the Moshi region compared to Dar es Salaam, 28 % compared to 17 %. This 
confirms that co-trimoxazole or per-oral penicillin should not be used as empirical treatment 
of pneumonia in this area, while amoxicillin could still be the first drug of choice. The 
majority of the isolates with reduced susceptibility for penicillin had intermediate resistance 
and this means that high doses of intravenous penicillin still can be used as treatment for 
hospitalised patients.  
 
Interestingly, when pneumococcal carriage was related to social factors and the health status 
of the children, significantly more children with pneumococci had had malaria compared to 
children without pneumococcal carriage (44% vs 12%).  Malaria is still a lethal threat against 
children in Tanzania and low-income countries in general, but is not known to increase the 
carriage of pneumococci. Malaria was earlier treated with a medicine that shares some 
components with co-trimoxazole (pyrimethamine-sulphadoxine).(28) Notably, almost all 
isolates in this study was non-susceptible against co-trimoxazole.  
 
Diseases known to increase the risk of pneumococcal carriage are HIV and measles (2) but 
none of the children included in the study had a history of measles or known HIV diagnosis. 
21 % of the non-carriers had a history of respiratory tract infection during the last three 
months versus 12 % of the carriers, although the difference was not significant one can 
speculate if the children with respiratory infection had been treated with antibiotics recently 
and therefore carried pneumococci to a lower extent.  
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 A few other studies have been performed in Moshi investigating pneumococcal carriage in 
relation to risk factors. 
One study investigated carriage in children to HIV-infected mothers born at KCMC between 
2005 and 2009. The colonization rate was 56 % and having siblings less than 10 years of age 
was a significant risk-factor for carriage whilst hospitalization was negatively associated with 
pneumococcal carrige.(29) Another longitudinal study was performed at a sugar-plantation in 
Moshi 2011, where naso- and oropharyngeal samples were taken from 83 healthy children 
under five years of age and those found to carry pneumococci were followed over a 12-month 
period. In this thesis the carriage rate was the same as in this study i.e. 29 %.(28) The 
pneumococcal carriage was higher in children with siblings but antibiotic use did not affect 
the rates.(28)  
 
When comparing the group of pneumococcal carriers to the children not carrying 
pneumococci in the present study, there was no difference in proportion of children with 
antibiotic treatment within the last three months (52 % compared to 49 %), anyone smoking 
in the household (16 % compared to 14 %) or living in a crowded home -in this study counted 
as living four or more persons per room in the household (16 % compared to 14%). A 
smoking member of the household and living in crowded homes are known risk factors for 
carriage of S. pneumoniae (1) but previous antibiotic use has in studies from Kenya and 
Malawi been shown both to decrease carriage and to increase the rates of non-susceptible 
pneumococci.(4, 13) Notably as many as half of the children had received antibiotics during 
the last three months. We observed during the study that many of the children had got 
antibiotic for questionable reasons, for example due to running nose only. In contrary to our 
beliefs the antibiotics were often prescribed by a doctor and not bought over counter. All the 
children in this study that had received antibiotics the last week had got it prescribed.  
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Interestingly, within the population of breastfeeding children 0-6 months (in total 68 children 
of whom 16 carried pneumococci) mixfeeding, i.e. a combination of food and breastfeeding, 
were more common in children not carrying pneumococci than children with pneumococci, 
and exclusively breastfeeding tended to be more common among pneumococcal carriers than 
children without pneumococci. This is in contrast to other studies where exclusive 
breastfeeding has been found as a protective factor for pneumonia.(10, 14) 
 
Of the 150 infants included in the study 59 % were partially or fully vaccinated against 
pneumococci. However no significant difference in carriage rate was observed between the 
vaccinated and non-vaccinated children.  It will be interesting to see how the carriage rate and 
spread of bacteria with reduced susceptibility to antibiotics is affected when the vaccine-
coverage will be even higher in the future.   
 
Although not statistically proven there was a higher percentage of mothers going up to 
primary school level in the group of carriers and a higher percentage of mothers going up to 
secondary school in the group of non-carriers. This could be an indication of the fact that 
lower socio-economic status increases the carriage-risk(11), and there was also a tendency of 
higher percentage of the fathers going to university in the non-carrier group, which may 
indicate that higher education is more common among the parents of children not carrying 
pneumococci.  
Strengths and weaknesses 
The number of 150 healthy children included in the study makes up a decent sample size, 
although the number of found pneumococci is too small to really correlate to social factors. 
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 This study has some weaknesses. The study is based on information recalled by parent, this is 
of course not without problem and can cause recall bias, since parents tend to forget, for 
instance recent antibiotic use, name of antibiotic, recent respiratory tract infection etc.  
However, the parents had some time to think through the questions before answering and 
many of the questions were asked repeatedly but in different ways, which could help the 
parents to remember. The questioning of the parents was also done in English but translated to 
the parents in Kiswahili, by the community health nurses, which of course may lead to 
misinterpretations. 
Despite some limitations at the clinical laboratory, for instance frequent power cuts and the 
delay of the laboratory package sent from University of Gothenburg, the laboratory work 
proceeded smoothly. 
Conclusions 
The findings in this study confirm that co-trimoxazole or per-oral penicillin not should be 
used as empirical treatment of pneumonia in this area, while amoxicillin could still be the first 
drug of choice. The high resistance rates against penicillin and co-trimoxazole, and the high 
rate of previous antibiotic treatment of the children suggests that more restrictions on the 
antibiotic use are needed in the Moshi area. 
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 Populärvetenskaplig sammanfattning på Svenska 
Lunginflammation är ett stort hälsoproblem i världen och låginkomst-länder är särskilt 
drabbade både av sjukdoms- och dödsfall. Några som är extra sårbara för att drabbas är små 
barn och lunginflammation är den sjukdom som dödar flest barn under fem års ålder i världen. 
Det finns olika virus och bakterier som orsakar lunginflammation men en bakterie som orsakar 
många sjukdomsfall är Streptococcus pneumoniae eller pneumokocken som den också kallas. 
Denna bakterie kan även ge andra infektioner såsom öroninflammation eller 
hjärnhinneinflammation. År 2000 beräknades pneumokocken orsaka nästan en miljon dödsfall. 
Som behandling mot lunginflammation finns olika sorters antibiotika, där framförallt 
penicillin är ett viktigt läkemedel. Ett ökande problem i världen är bakterier som har resistens 
mot olika antibiotika och pneumokocker med nedsatt känslighet för exempelvis penicillin kan 
både ge mer allvarliga och svårbehandlade infektioner. 
Denna studie gick ut på att undersöka bärarfrekvensen av S. pneumoniae i bakre svalget hos 
friska barn under två års ålder i Moshi i norra Tanzania, ett land där lunginflammation står för 
femton procent av dödsfallen hos barn under fem år. Förutom att undersöka hur många barn 
som bar på bakterien undersöktes även känsligheten för olika antibiotika hos de 
pneumokocker som hittades. Genom ett frågeformulär undersöktes levnads- och hälsofaktorer 
som kan öka risken för bärarskap; såsom trångboddhet, vedeldning inomhus, sjuk i mässling 
eller HIV, tidigare antibiotikaanvändning och så vidare.  
Bland de 150 barn som inkluderades i studien var det 43 stycken som bar på bakterien. Bland 
de pneumokocker som hittades var det många som hade nedsatt känslighet för penicillin och 
nästan alla var resistenta mot ett annat vanligt antibiotikum som kallas trim-sulfa. Detta 
innebär att mer riktlinjer för antibiotikaanvändning behövs i i Moshi-regionen samt att 
vaccinet mot pneumokocker som nu är inkluderat i barnvaccinations-programmet i Tanzania 
kan göra stor nytta. 
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 Appendix 
 
Appendix 1. Patient Questionnaire 
 
Consent Form 
 
Hello. My name is ……………………………………..a researcher/nurse/clinician working at 
KCMC/ KCMU-College. We are conducting a study in collaboration with the office of DMO, 
Moshi Municipality, KCMU Co/KCMC and Gothenburg University. The study is looking at 
prevalence of Streptococcus pnemoniae carriage, sensitivity patterns to common drugs and 
associated risk factors among children less than 2 years in the district. This bacteria/bug is the 
most cause of pneumonia in children. Rapid treatment of pneumonia once a child has 
symptoms is vital and drugs given need to be sensitive/ effective. However there is a problem 
that the bacteria develop resistance to the common drugs that are used by doctors/clinicians in 
our setting. This study therefore wants to collect sample from the child nose. This will be 
processed at the laboratory at KCMC to show if the child is carrying the bacteria and if that 
type of bacteria responds to the normal used drugs. The results from this study will help the 
government, the district and health providers to adapt/ change treatment of pneumonia/ IMCI 
taking into account the sensitivity pattern of drugs.   
 
Your permission for the child to participate is very important as the success of this study 
depends much on you, by giving us your sincere answers. I guarantee the information which 
will be provided to me will be confidential and used by members of the study alone and your 
name or the name of the child will not appear in any data or report. 
 
Participation is voluntary and you can withdraw to be part of this study at any time, without 
affecting your right of services or care at this clinic. 
 
I have been informed fully about my child participating in this research including the risks 
and advantages. I voluntary agree to participate fully in this study for the beneficence of child 
health as I have been informed 
 
Interviewee signature……………………   Parent/Guardian Signature………………….…… 
Date………………………………….….    Date……………………………………………… 
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 Patient Questionnaire 
 
Pneumococci in healthy children and in children with respiratory tract infections in Moshi, 
Tanzania 
 
 
ID Number of participant:………………….. 
1. Name of the facility……………………… 
2. Level  1. Health centre 2. Dispensary 
3. Main reasons for attending at health facility; tick the appropriate & multiple answers are 
possible 
      a. Vaccination of the child 
      b. Growth monitoring  
      c. OPD clinic (child is sick); symptoms………………………………………………………. 
      d. CTC clinic 
       e. Others; mention…………………………………………………………………………. 
4. Date of filling questionnaire………………………………………………………………… 
5. Name of the person filling the questionnaire………………………………………………… 
 
 
1. Date of birth of the child…………………………………… 
Age in months....................................................................................................................... 
 
2. Weight (Kgs)...................................................................................................................... 
 
3. Length (cm)........................................................................................................................ 
 
4. Gender Girl 
 Boy 
 
5. Delivery on time (meaning term or preterm baby)? 
Yes 
No, Divergence (weeks)......................................................................................... 
 Unknown 
 
6. Problems during delivery? 
No  
 Yes, Which.............................................................................................................. 
 
7. Problems during neonatal period? 
No  
 Yes, Which.............................................................................................................. 
 
8. Is the child still Breastfeeding? 
 
0. No   1.Yes 
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If YES still breastfeeding; (For children aged 0-5 months)  
  
 No  Yes 
    Have you started giving water to the child?............................................................................. 
    Have you started giving cow’s milk to the child?.................................................................... 
    Have you started giving porridge to the child?........................................................................ 
    Have you started giving juice/ soup to the child?.................................................................... 
    Have you started giving semisolids e.g. mtori?....................................................................... 
    Have you started giving solids e.g. ugali with stew?............................................................... 
 
After filling the questions above, please tick if the child is still EBF, predominantly or mixfed 
Exclusive.............................Predominantly BF............................Mix feeding…………… 
 
 
IF YES still breastfeeding; (For children aged 6 months or more) 
     Have you introduced other foods?  No  Yes 
 
IF NOT BREASTFEEDING: 
      Age of the child in months when breastfeeding was stopped……………………...... 
      The child has never been breastfed.............................................................................. 
 
 
9. Reason for clinical visit?........................................................................................................ 
 
10. Does the child have the any of the following symptoms of respiratory tract infection 
today? 
No  Yes 
Fever   ________  ________ 
Chills   ________  ________ 
Rapid or difficult breathing ________  ________ 
Cough   ________  ________ 
Running nose  ________  ________ 
Sore Throat   ________  ________ 
 Other:....................................................................................................................... 
 
11. Sudden onset of symptoms? 
 No 
 Yes 
 Unknown 
 
12. Has anyone else in your family had similar symptoms as your child in the last 14 
days? 
 No 
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  Yes 
 Unknown 
 
13. Has the child used any antibiotics the week (7 days) before seeking medical care? 
No  
Yes, which.............................................................................................................. 
 
Prescribed................................................Over the counter..................................... 
 
14. Has the child used cough medicine? 
 No 
 Yes, which (or contents)......................................................................................... 
 
15. Has the child used any antibiotics in the previous? 
    No Yes If yes; types 
 One month prior to interview _____ ____ __________ 
 Unknown 
  
Three months prior to interview _____ ____ __________ 
Unknown 
 
16. Has your child had any of the following respiratory tract infections (cough with 
fever, rapid breathing, difficulty in breathing, pneumonia) within the past 3 months? 
 No  
Unknown 
Yes, how many times:.............................................................................................  
 
Symptoms:.............................................................................................................. 
 
Antibiotic treatment given....................................................................................... 
  
17. Current or previous diseases  No Yes When 
 
Asthma.....................................................................................................................
Gastrointestinal infections....................................................................................... 
Measles.................................................................................................................... 
Malaria..................................................................................................................... 
HIV.......................................................................................................................... 
Lung tuberculosis.................................................................................................... 
Malformations......................................................................................................... 
Heart disease............................................................................................................ 
Other....................................................................................................................... 
 
Details (symptoms, treatment, number of times): 
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................................................................................................................................. 
 
.................................................................................................................................  
 
18. Has the child been hospitalized within the past 3 months? 
 No  
 Yes, When............................................................................................................... 
        Why................................................................................................................. 
 
 
19. Area where you are living? 
 Type   Name of ward 
Rural area………………………………………………………………………… 
 Semi-rural area, Size............................................................................................... 
 Semi-urban, Size..................................................................................................... 
 Urban area, Size...................................................................................................... 
 
20. Parents level of education?  
Mother    Father 
⁪ Never been to school   ⁪ Never been to school 
⁪ Primary school   ⁪ Primary school  
⁪ Secondary school   ⁪ Secondary school 
⁪ University    ⁪ University 
 
 
21. Parents current occupation?   
Mother    Father 
⁪ Employed. What....................................................... ⁪Employed. What................................ 
⁪ Self employed. What................................................ ⁪Self employed.What.......................... 
⁪ Unemployed   ⁪ Unemployed 
⁪ Student    ⁪ Student 
⁪ Other..............................................................................Other.................................................. 
 
 
22. How many siblings does this child have?.......................................................................... 
 
23. In total how many people live in your household?............................................................ 
 
Out of those how many are children under five?................................................................... 
 
24. Number of rooms in your home?......................................................................................... 
 
25. Number of people sleeping in the same room?................................................................... 
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 26. Smoking of parents or other persons in the household? 
 Yes 
 No 
 
27. How does your family cook food? 
 Electricity 
 Gas 
 Opem fire outside 
 Open fire with chimney 
 Open fire without chimney 
 
 
27. Is your child vaccinated? Please tick vaccinations the child has received 
 
 Birth 6 weeks 10 weeks 14 weeks 9 months 18 months  
BCG        
OPV        
OPV 1        
OPV 2        
OPV 3        
Heptavalent 1 (DPT, Hep B, 
Hemophilus B) 
       
Heptavalent 2 (DPT, Hep B, 
Hemophilus B) 
       
Heptavalent 3 (DPT, Hep B, 
Hemophilus B) 
       
PCV 13 – 1        
PCV 13 – 2        
PCV 13 – 3        
Measles        
Others:        
Others:        
Others:        
 
Unknown…………………………………………………………………………………….. 
Adequately immunized for age: No  Yes 
 
 
28. If the child has siblings < 1 year, have they been vaccinated against pneumococci?  
 Yes 
 No  
 Unknown 
 
Thank you for your participation! 
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